Loading...
ROCO
4195
Market cap42mUSD
Jun 04, Last price  
17.00TWD
Name

Genomics Bioscience & Technology Co Ltd

Chart & performance

D1W1MN
ROCO:4195 chart
P/E
—
P/S
1.92
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.45%
Rev. gr., 5y
9.83%
Revenues
708m
+46.74%
427,652,000443,176,000389,965,000419,003,000396,142,000482,754,000708,375,000
Net income
-39m
L-82.33%
18,174,000619,00018,738,00071,596,000-168,066,000-223,097,000-39,427,000
CFO
-87m
L-22.35%
78,337,000-18,833,000-27,763,000-21,129,000-96,024,000-111,768,000-86,789,000
Dividend
Aug 08, 20230.102 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array of services within the field of genomic sequencing. Its core offerings encompass standard and intricate DNA sequencing, including TAF-certified options, with clients also benefiting from complimentary sequencing primer and primer walking services. Beyond sequencing, the company is proficient in synthesizing peptides, genes, and oligonucleotides. Furthermore, its analytical capabilities extend to crucial laboratory services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. The firm also delivers advanced sequencing solutions, including genome-level, targeted, gene regulation, and metagenomic sequencing, alongside cutting-edge third-generation sequencing technologies. To support these services, it offers integrated sequencing platforms and streamlined workflows. Additionally, Genomics BioSci & Tech. Co.,Ltd. provides specialized diagnostic screenings, such as non-invasive prenatal testing (NIPT), spinal muscular atrophy (SMA) carrier screening, and fragile X syndrome premutation screening. Established in 2001, the company's headquarters are located in New Taipei City, Taiwan.

Key people

Mengxian Zhou
Chairman of the Board · since 2021
Zuo-wei Zhang
Chief Financial Officer, Corporate Governance Officer · since 2023
Shengda Xu
Chief Information Officer · since 2023
Junsheng Liu
Deputy General Manager-Proteome & Metabolism Business Group · since 2013
Weiqun Zhang
Deputy General Manager-Finance
Hanming Zhang
Deputy General Manager-Next Generation Sequencing Business Group · since 2013
Shufen Zhang
Head of Finance & Accounting · since 2022
Junqi Jiang
Chief Executive Officer, Chief Technology Officer, General Manager, Director · since 2023
Wanqi Li
Director · since 2021
Shijia Lin
Director · since 2022
Zuowei Zhang
Chief Operating Officer, Deputy General Manager-Life Technology Business Group, Director · since 2021
Yingting Zhao
Director · since 2018
Renhong Cheng
Independent Director · since 2023
Yu-Jen Hsiao
Independent Director · since 2021
Jei-Fu Shaw
Independent Director · since 2021
IPO date
Dec 16, 2013
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT